Eisai

follow Follow

Company

select Filter
All
Business
Culture
Environment
Health
Politics
Research

Key facts

Latest news

Japan's Eisai to invest in U.S. Alzheimer's blood testing firm C2N

Read: Nikkei

2024-03-06

Eisai seeks expanded use of Alzheimer's drug for prevention

Read: Nikkei

2023-12-22

After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

Read: ABC News

2023-09-26

Metrics

Business

assets 8.6B $
Debt 658.7M $
free cash flow 414,082,000.00
market cap 11,721,900,000.00
profits 332.9M $


Visualizations

Datasets

Source

Twitter, YAHOO-FIN, YFINANCE

Updated: 2 days ago

License

CC BY 4.0

Going further